Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies
Conditions
Keywords
acute myeloid leukemia, AML, myelodysplastic syndrome, MDS, dual mutation, MPN, AITL, hematologic malignancies, IDH1, IDH2, AG-881
Brief summary
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that harbor an IDH1 and/or IDH2 mutation
Detailed description
The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-881 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where patients will receive AG-881 to further evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs or the patient is removed at the discretion of the investigator.
Interventions
DRUGAG881
AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
Sponsors
Agios Pharmaceuticals, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must be ≥18 years of age Patients must have documented IDH1 and/or IDH2 gene-mutated disease Patients must have an advanced hematologic malignancy with an IDH1 and/or IDH2 mutation Patient must be able to understand and willing to sign an informed consent Patients must have ECOG PS of 0 to 2 Patients must have adequate hepatic function as evidenced by serum total bilirubin ≤1.5 upper limit of normal (ULN), unless considered due to Gilbert's disease or leukemic involvement Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤3.0 × ULN, unless considered due to involvement by the neoplasm under consideration for treatment Patients must have adequate renal function as evidenced by a serum creatinine ≤2.0 × ULN or Creatinine clearance 40 mL/min based on the Cockroft-Gault glomerular filtration rate (GFR) estimation Patients must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of therapy. Patients with reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy or tubal occlusion or who have not been naturally postmenopausal (i.e., who have not menstruated at all) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
Exclusion criteria
Patients who have undergone HSCT within 60 days Patients who received systemic anticancer therapy or radiotherapy \<14 days prior to their first day of study drug administration Patients who received an investigational agent \<14 days prior Patients who are pregnant or breast feeding Patients with an active severe infection who require anti-infective therapy or with an unexplained fever \>38.5°C during Screening visits or on their first day of study drug administration (at the discretion of the Investigator, patients with tumor fever may be enrolled) Patients with New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF \<40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan within approximately 28 days of C1D1 Patients with a history of myocardial infarction within the last 6 months Patients with known unstable or uncontrolled angina pectoris Patients with a known history of severe and/or uncontrolled ventricular arrhythmias Patients with QTc interval ≥450 msec or with other factors that increase the risk of QT prolongation or arrhythmic events Patients taking medications that are known to prolong the QT interval Patients with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C Patients with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is a clinical suspicion of CNS involvement by leukemia during Screening Patients with immediately life-threatening, severe complications of hematologic malignancies such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety/tolerability; incidence of adverse events | Up to 26 weeks, on average |
| Maximum Tolerated Dose and/or the recommended Phase II dose of AG-881 in patients with advanced hematologic malignancies | Up to 26 weeks, on average |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics of AG-881 in patients with advanced hematologic malignancies | Up to 26 weeks, on average |
| Pharmacodynamic levels of AG-881 | Up to 26 weeks, on average |
| Pharmacodynamic levels of 2-HG | Up to 26 weeks, on average |
| Clinical Activity according to the 2003 revised IWG criteria for AML, the 2006 modified IWG criteria for MDS, disease-specific response criteria for other hematologic malignancies | Up to 26 weeks, on average |
Countries
France, United States
Outcome results
None listed